mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
Company profile
Ticker
VRAYQ
Exchange
Website
CEO
Scott William Drake
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical ...
Former names
Mirax Corp
SEC CIK
Corporate docs
Subsidiaries
ViewRay Technologies, Inc. • ViewRay GmbH ...
VRAYQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
8 Sep 23
8-K
Regulation FD Disclosure
7 Sep 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Other Events
3 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Jul 23
8-K
Entry into a Material Definitive Agreement
17 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jun 23
SD
Conflict minerals disclosure
26 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
Transcripts
VRAYQ
Earnings call transcript
2023 Q1
10 May 23
VRAYQ
Earnings call transcript
2022 Q4
27 Feb 23
VRAYQ
Earnings call transcript
2022 Q3
2 Nov 22
VRAYQ
Earnings call transcript
2022 Q2
3 Aug 22
VRAYQ
Earnings call transcript
2022 Q1
8 May 22
VRAYQ
Earnings call transcript
2021 Q4
25 Feb 22
VRAYQ
Earnings call transcript
2021 Q3
7 Nov 21
VRAYQ
Earnings call transcript
2021 Q2
8 Aug 21
VRAYQ
Earnings call transcript
2021 Q1
9 May 21
VRAYQ
Earnings call transcript
2020 Q4
5 Mar 21
Latest ownership filings
SC 13G/A
BlackRock Inc.
8 Aug 23
4
Sanket Shah
26 Jul 23
4
Adam Andrew Podbelski
26 Jul 23
3
Sanket Shah
26 Jul 23
3
Adam Andrew Podbelski
26 Jul 23
144
Notice of proposed sale of securities
25 Jul 23
SC 13D/A
EBRAHIMI FARHAD FRED
25 Jul 23
4
B KRISTINE JOHNSON
24 Jul 23
4
FARHAD FRED EBRAHIMI
21 Jul 23
144
Notice of proposed sale of securities
21 Jul 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 85.53 mm | 85.53 mm | 85.53 mm | 85.53 mm | 85.53 mm | 85.53 mm |
| Cash burn (monthly) | 18.99 mm | 8.26 mm | 9.88 mm | 9.45 mm | 17.87 mm | 9.41 mm |
| Cash used (since last report) | 157.34 mm | 68.45 mm | 81.85 mm | 78.27 mm | 148.06 mm | 77.98 mm |
| Cash remaining | -71.81 mm | 17.08 mm | 3.68 mm | 7.26 mm | -62.52 mm | 7.55 mm |
| Runway (months of cash) | -3.8 | 2.1 | 0.4 | 0.8 | -3.5 | 0.8 |
Institutional ownership, Q2 2023
72.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 124 |
| Opened positions | 16 |
| Closed positions | 61 |
| Increased positions | 33 |
| Reduced positions | 49 |
| 13F shares | Current |
|---|---|
| Total value | 42.85 bn |
| Total shares | 131.96 mm |
| Total puts | 2.37 mm |
| Total calls | 1.41 mm |
| Total put/call ratio | 1.7 |
| Largest owners | Shares | Value |
|---|---|---|
| Hudson Executive Capital | 15.75 mm | $5.55 bn |
| Artisan Partners Limited Partnership | 14.55 mm | $5.13 bn |
| FOSUF Fosun International | 11.98 mm | $4.19 bn |
| Vanguard | 10.51 mm | $3.70 bn |
| BLK Blackrock | 9.96 mm | $3.51 bn |
| Pura Vida Investments | 8.76 mm | $3.09 bn |
| Sio Capital Management | 6.43 mm | $2.27 bn |
| FMR | 5.38 mm | $1.89 bn |
| Aisling Capital II | 3.75 mm | $39.46 mm |
| Jacobs Levy Equity Management | 3.15 mm | $1.11 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jul 23 | Johnson B Kristine | Common Stock | Sell | Dispose S | No | No | 0.052 | 30,702 | 1.60 k | 126,720 |
| 21 Jul 23 | Prange Karen | Common Stock | Sell | Dispose S | No | No | 0.051 | 37,600 | 1.92 k | 8,799 |
| 19 Jul 23 | Prange Karen | Common Stock | Sell | Dispose S | No | No | 0.075 | 91,866 | 6.89 k | 46,399 |
| 19 Jul 23 | Castelein Caley | Common Stock | Sell | Dispose S | Yes | No | 0.071 | 1,545,600 | 109.74 k | 0 |
| 19 Jul 23 | Castelein Caley | Common Stock | Sell | Dispose S | No | No | 0.07 | 641,033 | 44.87 k | 99,047 |
| 19 Jul 23 | Castelein Caley | Common Stock | Sell | Dispose S | No | No | 0.068 | 158,397 | 10.77 k | 740,080 |
| 19 Jul 23 | Paul Ziegler Jr | Common Stock | Sell | Dispose S | No | No | 0.072 | 169,785 | 12.22 k | 1,425,141 |
| 18 Jul 23 | Scott William Drake | Common Stock | Sell | Dispose S | No | No | 0.0622 | 2,408,747 | 149.82 k | 1,591,615 |